In August 2007, the FDA approved Fenoglide for the treatment of dyslipidemia in the United States. Veloxis has out-licensed the commercial rights of Fenoglide for the United States, Canada and Mexico.
The commercial rights are held by Santarus Inc, and were transferred in the first quarter of 2012 from Shore Therapeutics Inc.
AtorFen, which has completed Phase II clinical studies for the treatment of dyslipidemia, is a combination therapy based on a fixed-dose combination of atorvastatin (the active ingredient in Lipitor) and a low dose of fenofibrate without food effect. Thus, the product candidate is designed to combine in a small tablet a proven statin and a fenofibrate in a treatment that addresses all three atherosclerosis risk parameters: Elevated LDL, elevated triglycerides and low HDL.
Dec 19, 2014
Veloxis Comments on U.S. District Court Order